OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Steiner on a Microdevice for Evaluating Responses to RCC Treatment

August 9th 2024

Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.

Dr Machaalani on the Interaction Between c-Met and AXL in RCC

August 9th 2024

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast Cancer

August 9th 2024

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Dr Leidner on the Multivalent Vaccine DPV-001 in Advanced or Metastatic HNSCC

August 8th 2024

Rom S. Leidner, MD, discusses data for DPV-001 combined with PD-1inhibition with or without a GITR agonist in advanced or metastatic HNSCC.

Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLC

August 8th 2024

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Dr Westin on the FDA Approval of Durvalumab Plus Chemo in dMMR Endometrial Cancer

August 8th 2024

Shannon Westin, MD, MPH, FACOG, discusses the FDA approval of durvalumab plus chemotherapy in dMMR advanced or recurrent endometrial cancer.

Dr Perez on the Efficacy and Safety of Frontline Petosemtamab Plus Pembrolizumab in HNSCC

August 8th 2024

Cesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.

Dr Bekaii-Saab on the Final Analysis of MOUNTAINEER in HER2+ CRC

August 8th 2024

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

Dr Friedlander on the Duravelo-2 Trial for Advanced or Metastatic Urothelial Cancer

August 8th 2024

Terence W. Friedlander, MD, discusses the investigation of BT8009 in the Duravelo-2 study in patients with advanced or metastatic urothelial cancer.

Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

August 8th 2024

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 8th 2024

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Dr Shallis on the Utility of Luspatercept in the ELEMENT-MDS Trial in MDS

August 8th 2024

Rory Shallis, MD, discusses the utility of luspatercept in the context of the phase 3 ELEMENT-MDS trial for patients with myelodysplastic syndrome.

Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC

August 7th 2024

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Dr Kelly on the Treatment and Heterogeneity of GIST

August 7th 2024

Ciara Kelly, MBBCh, BAO, discusses how the heterogeneity of GIST affects treatment decisions and the importance of testing for genetic abnormalities.

Dr Lentzsch on Results for Linvoseltamab in Heavily Pretreated R/R Myeloma

August 7th 2024

Suzanne Lentzsch, MD, PhD discusses data for linvoseltamab in patients with relapsed/refractory multiple myeloma

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm

August 7th 2024

Erika P. Hamilton, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-low breast cancer.

Dr Bekaii-Saab on the Benefits of Multidisciplinary Conferences in GI Cancer Care

August 7th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the benefits of multidisciplinary conferences within the gastrointestinal cancer treatment field.

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

August 6th 2024

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Dr Ramsey on Signs and Symptoms of Pneumonitis in Locally Advanced NSCLC

August 6th 2024

Meghan Ramsey, MD, discusses signs and symptoms of pneumonitis in locally advanced non–small cell lung cancer.

Dr Danilov on the Importance of Using BTK as a Target in CLL Treatment

August 6th 2024

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.